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The aim of this study was to evaluate the effects of caffeine, tea polyphenol and daidzein on the 
pharmacokinetics of lansoprazole and its metabolites. Rats were intragastrically administered caffeine 
(30 mg·kg-1, once per day), tea polyphenol (400 mg·kg-1, once per day) or daidzein (13.5 mg·kg-1, once 
per day) for 14 days, followed by an intragastric administration of lansoprazole (8 mg·kg-1) on the 15th 
day. The plasma concentrations of lansoprazole and its two primary metabolites, 5-hydroxylansoprazole 
and lansoprazole sulfone, were determined by high-performance liquid chromatography coupled with 
tandem mass spectrometry (HPLC-MS/MS). Tea polyphenol significantly elevated the Area Under the 
Curve (AUC) of lansoprazole from 680.29 ± 285.99 to 949.76 ± 155.18 μg/L.h and reduced that of 
lansoprazole sulfone from 268.82 ± 82.37 to 177.72 ± 29.73 μg/L.h. Daidzein increased the AUC of 
lansoprazole from 680.29 ± 285.99 to 1130.44 ± 97.6 μg/L.h and decreased that of lansoprazole sulfone 
from 268.82 ± 82.37 to 116.23 ± 40.14 μg/L.h. The pharmacokinetics of 5-hydroxylansoprazole remained 
intact in the presence of tea polyphenol or daidzein. Caffeine did not affect the pharmacokinetics of 
lansoprazole and its metabolites. The results imply that tea polyphenol and daidzein may inhibit the in 
vivo metabolism of lansoprazole by suppressing CYP3A.
Uniterms: Lansoprazole/pharmacokinetics. Caffeine/effects/lansoprazole pharmacokinetics. Tea 
polyphenol/effects/lansoprazole pharmacokinetics. Daidzein/effects/lansoprazole pharmacokinetics. 
5-hydroxylansoprazole. Lansoprazole sulfone. Hepatic microsomal enzyme/inhibition.
O objetivo deste estudo foi avaliar os efeitos da cafeína, do polifenol do chá e da daidzeína na 
farmacocinética do lansoprazol e de seus metabólitos. Administraram-se, intragastricamente, aos ratos 
cafeína (30 mg·kg-1, uma vez ao dia), polifenol do chá(400 mg·kg-1, uma vez ao dia) ou daidzeína (13,5 
mg·kg-1, uma vez ao dia), por 14 dias, seguindo-se a administração de lansoprazol (8 mg·kg-1) no 15º. dia. 
As concentrações plasmáticas do lansoprazol e de seus dois metabólitos primários, 5-hidroxilansoprazol 
e sulfona de lansoprazol, foram determinadas por cromatografia líquida de alta eficiência acoplada com 
espectrometria de massas (CLAE-EM/EM). O polifenol do chá elevou, significativamente, a Área Sob a 
Curva (ASC) do lansoprazol de 680,29 ± 285,99 para 949,76 ± 155,18 μg/L.h e reduziu a da sulfona de 
lansoprazol de 268,82 ± 82,37 para 177,72 ± 29,73 μg/L.h. A daidzeína aumentou a ASC do lansoprazol 
de 680,29 ± 285,99 para 1130,44 ± 97,6 μg/L.h e reduziu a da sulfona de lansoprazol de 268,82 ± 82,37 
para 177,72 ± 29,73 μg/L.h. A farmacocinética do 5-hidroxilansoprazol permaneceu intacta na presença 
de polifenol do chá ou daidzeína. A cafeína não afetou a farmacocinética do lansoprazol e de seus 
metabólitos. Os resultados sugerem que o polifenol do chá e a daidzeína podem inibir o metabolismo 
in vivo do lansoprazol por supressão da CYP3A. 
Unitermos: Lansoprazol/farmacocinética. Cafeína/efeitos/farmacocinética do lansoprazol. 
Polifenol/efeitos/farmacocinética do lansoprazol. Daidzeína/efeitos/farmacocinética do lansoprazol. 
5-Hidroxilansoprazol. Sulfona de lansoprazol. Enzima microssômica hepática/inibição.
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INTRODUCTION
The possible interaction between dietary factors 
and drugs, which has recently come into focus, is 
readily observed as cytochrome P450 (CYP450) enzyme 
inhibition. For instance, grapefruit juice can inhibit 
the activity of hepatic microsomal enzyme CYP3A4, 
and betel nut, coconut and garlic exert inhibitory 
effects on the activity of CYP2E1 (Nowack, 2008; 
Britto et al., 1991). Taking these foods simultaneously 
slows the metabolism of the drugs involved, elevates 
the plasma concentration, and leads to adverse drug 
reactions.
Lansoprazole, which is a proton pump inhibitor, is 
typically used to treat peptic ulcers. As a potent antacid, 
lansoprazole inhibits gastric acid secretion, reinforces 
the defense of gastric parietal cells and accelerates ulcer 
healing by suppressing H+/K+-ATP enzymatic activity. 
In addition, lansoprazole shows superb performance 
in eradicating gastric Helicobacter pylori (Inoue et al., 
2010). These characteristics have allowed lansoprazole 
to be widely used in treating gastric acid-related diseases, 
such as gastric ulcer, gastroesophageal reflux disease and 
Zollinger-Ellison syndrome (Spencer, Faulds, 1994). 
Thus, the possible interactions between lansoprazole and 
other drugs and foods need to be carefully considered. 
Lansoprazole is metabolized into 5-hydroxylansoprazole 
and lansoprazole sulfone primarily by CYP2C19 and 
CYP3A at low and high concentrations, respectively. 
CYP2C19 is polymorphic, which has significant 
effects on the pharmacokinetics of lansoprazole and 
its metabolites. The differences in pharmacokinetics 
between CYP2C19 extensive metabolizers and poor 
metabolizers are more significant for lansoprazole 
sulfone than for 5-hydroxylansoprazole (Zhang et al., 
2012). Therefore, any food components metabolized by 
CYP2C19 or CYP3A, especially those that affect CYPs, 
may influence the pharmacokinetics of lansoprazole in 
vivo (Saito et al., 2005).
Dietary factors, such as coffee and tea consumption 
together with soy products, impact drug absorption and 
metabolism via multiple mechanisms. Consequently, 
the plasma concentrations of drugs are affected, adverse 
drug reactions are induced, and the therapeutic effects 
of the drugs are altered. Caffeine, tea polyphenol 
and daidzein, which are the main active ingredients 
of coffee, tea and beans, respectively, were utilized 
in this study to clarify their influences on the in vivo 
pharmacokinetics of lansoprazole and its major 
metabolites, 5-hydroxylansoprazole and lansoprazole 
sulfone, in rats.
MATERIAL AND METHODS
Material
Lansoprazole standard (National Institutes for 
Food and Drug Control, batch No.: 100709-200501), 
5-hydroxylansoprazole and lansoprazole sulfone standard 
(TLC Pharmachem Inc., batch No.: 1020-097A2), 
lansoprazole raw material (Jiangsu Aokang Group., Ltd., 
batch No.:F100502), Omeprazole (National Institutes for 
Food and Drug Control, batch No.: 20050509), caffeine 
(Beijing Yixiruisi Technology Ltd.), tea polyphenol 
(Anhui Province Tea Leaves Alkaloid Ltd., batch No.: 
080726), daidzein (Zhengzhou Biology Technology Ltd.), 
methanoic acid and ammonium acetate (analytically pure), 
acetonitrile (HPLC pure) and double distilled water.
Animal treatment
Male SD rats (7 weeks, 200 ± 20 g) were obtained 
from the Experimental Animal Center of Tongji Medical 
College of Huazhong, University of Science and 
Technology, China, and housed under controlled 
conditions. They were maintained on a 12:12 h light-dark 
cycle at a room temperature of 21 °C. Food and water were 
available ad libitum. All procedures were consistent with 
the National Institutes of Health guidelines for the care 
and use of laboratory animals. The protocol was approved 
by the Ethical Committee on Animal Experimentation of 
Tongji Medical College, Huazhong University of Science 
and Technology, China.
Pharmacokinetics study
Rats were randomly divided into 4 groups. Four 
groups of six rats each were separately fed caffeine 
(30 mg kg-1, dissolved in 0.5% carboxymethyl cellulose 
sodium aqueous solution, once per day), tea polyphenol 
(400 mg·kg-1, dissolved in double distilled water, once 
per day), daidzein (13.5 mg·kg-1, suspended in 0.5% 
carboxymethyl cellulose sodium aqueous solution, once 
per day) or physiologic saline (1 mL/100 g, once per day) 
for 14 consecutive days. One day after the last treatment, 
all rats were given lansoprazole (8 mg·kg-1) by gavage. 
Blood samples (0.3 mL) were taken from the jugular vein 
cannula with a heparinized syringe for the determination of 
the plasma concentration before and 0.08, 0.17, 0.25, 0.33, 
0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6 h after the administration. After 
the collection of each blood sample, an equal volume of 
heparinized 0.9% NaCl (20 U/mL) was administered to the 
animal. The samples were centrifuged at 3000 g for 10 min 
Effects of caffeine, tea polyphenol and daidzein on the pharmacokinetics of lansoprazole and its metabolites in rats 895
at 4 °C immediately after collection and stored at – 80 °C 
until analysis.
HPLC-MS/MS assay of lansoprazole and its 
metabolites
The plasma samples were treated with acetonitrile 
precipitation and omeprazole was used as the internal 
standard. A Diamonsil C18 column (5 μm, 150 × 2.1 mm) was 
used as the analytical column, with acetonitrile-0.1% (v/v) 
formic acid and 2 mmol·L-1 ammonium acetate (43:57, v/v) 
as the mobile phase at s flow rate of 0.3 mL/min. The samples 
were ionized by electrospray ionization in a triple quadruple 
tandem mass spectrometer, and the plasma lansoprazole, 
5-hydroxylansoprazole, lansoprazole sulfone and internal 
standard were determined with a multiple reaction-
monitoring mode of m/z 368.0→163.9, m/z 384.1→179.9, 
m/z 383.9→115.9 and m/z 326.0→280.1, respectively. The 
linearity was confirmed in the concentration range of 116.00-
46400.00 ng/mL, 12.60-5040.00 and 12.40-4960.00 ng/mL 
for lansoprazole, 5-hydroxylansoprazole, and lansoprazole 
sulfone in rat plasma. The inter-assay and intra-assay CVs 
of the analysis of the low, medium and high concentration 
samples for lansoprazole, 5-hydroxylansoprazole and 
lansoprazole sulfone were all less than 10%. The recovery 
was determined for six replicates of rat plasma with low, 
medium and high concentrations of the three analytes 
(232.00, 6200.00, 37120.00 ng/mL for lansoprazole, 25.20, 
670.00, 4032.00 ng/mL for 5-hydroxylansoprazole, and 
24.80, 660.00, 3968.00 ng/mL for lansoprazole sulfone). 
The mean absolute extraction recovery of lansoprazole 
was 91.44±4.10%, 96.36±8.62% and 92.70±4.93%; 
the mean absolute recovery of 5-hydroxylansoprazole 
was 91.25±8.60%, 92.68±8.55% and 89.60±8.33%; 
and the mean absolute recovery of lansoprazole sulfone 
was 92.14±5.30%, 91.85±3.22% and 93.31±4.60%. 
The variability and recovery rates were suitable for 
pharmacokinetic analysis.
Statistical analysis
Pharmacokinetic parameters were calculated using 
the DAS software (Version 2.0, Sun Ruiyuan, China). The 
data were evaluated using the SPSS 13.0 software for an 
analysis of variance (ANOVA) followed by a Duncan’s 
multiple comparison test, and P values of less than 0.05 
were considered statistically significant.
RESULTS AND DISCUSSION
Quantitative basis
The concentration of lansoprazole and its metabolites 
(5-hydroxylansoprazole and lansoprazole sulfone) in rat 
plasma was determined by a HPLC-MS/MS method 
described in detail in our previous work (Liu, Xiang, Ren, 
2011). The HPLC-MS/MS method showed satisfactory 
results for the simultaneous determination of lansoprazole 
and its metabolites in rat plasma and was successfully used 
for the investigation of the pharmacokinetic interaction 
of lansoprazole with other drugs and chemicals (Xiang 
et al., 2012).
Lansoprazole pharmacokinetics
As shown in Figure 1, caffeine barely affected 
FIGURE 1 - Plasma concentration-time profiles of lansoprazole in rats after a single 8 mg·kg-1 oral dose of lansoprazole in groups 
with different pretreatments for two weeks. The values shown are the mean ± S.D. of six rats.
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TABLE I - In vivo pharmacokinetic parameters of lansoprazole in rats (–x ± S.D.,  n = 6)
Parameters Control group Caffeine Tea polyphenol Daidzein
AUC (μg/L.h) 680.29 ± 285.99 710.27 ± 77.39 949.76 ± 155.18* 1130.44 ± 97.69*
MRT (h) 1.76 ± 0.22 1.95 ± 0.26 1.92 ± 0.20 2.22 ± 0.14*
T1/2 (h) 1.94 ± 0.85 2.17 ± 1.33 3.54 ± 1.80* 3.327 ± 0.53*
Tmax (h) 0.40 ± 0.11 0.36 ± 0.23 0.39 ± 0.31 0.31 ± 0.10
CL (L/h/kg) 13.54 ± 9.08 9.75 ± 2.42 6.24 ± 1.70 5.18 ± 0.42*
Cmax (μg/L) 328.56 ± 136.69 323.33 ± 52.59 403.17 ± 55.34 427.00 ± 82.73
*p < 0.05 compared with the control group.
the plasma concentration of lansoprazole, but both tea 
polyphenol and daidzein, particularly the latter, increased 
the concentration. Table I shows the pharmacokinetic 
parameters of lansoprazole. The caffeine group was not 
significantly different from the control group. The AUC of 
lansoprazole in the rats administered tea polyphenol was 
1.4 times higher than that of the control group (p < 0.05), 
and the T1/2 of lansoprazole was also prolonged (p < 0.05). 
Daidzein remarkably elevated the AUC of lansoprazole 
(1.7 times), extended MRT and T1/2, and decelerated the 
clearance (p < 0.05).
5-Hydroxylansoprazole pharmacokinetics
The curves plotting the plasma concentrations of 
5-hydroxylansoprazole in each group versus time are 
shown in Figure 2. The plasma concentrations of all groups 
did not obviously differ. The pharmacokinetic parameters 
of 5-hydroxylansoprazole are shown in Table II. Tea 
polyphenol, daidzein and caffeine did not influence the 
pharmacokinetic parameters of 5-hydroxylansoprazole.
Lansoprazole sulfone pharmacokinetics
The dependences of the plasma concentrations 
of lansoprazole sulfone on time are plotted in Figure 3, 
indicating that tea polyphenol and daidzein, especially 
the latter, dramatically lowered the plasma concentration 
of lansoprazole sulfone. The pharmacokinetic parameters 
of lansoprazole sulfone are shown in Table III. Caffeine 
did not exert discernible effects on the pharmacokinetic 
parameters of lansoprazole sulfone. However, tea 
polyphenol significantly reduced the AUC of lansoprazole 
sulfone by 66% and Cmax, and slowed down its clearance 
in vivo (p < 0.05). The AUC of lansoprazole sulfone in 
the rats administered daidzein was markedly lowered, 
by 43%, compared to the control group, and the Cmax was 
also obviously decreased compared with the control group 
(p < 0.05).
The simultaneous intake of food and drugs is a 
ubiquitous protocol. The influences of food such as 
grapefruit juice and Carica papaya extract on drug 
pharmacokinetics have frequently been addressed 
FIGURE 2 - Plasma concentration-time profiles of 5-hydroxylansoprazole in rats after a single 8 mg·kg-1 oral dose of lansoprazole 
in groups with different pretreatments for two weeks. The values shown are the mean ± S.D. of six rats.
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TABLE II - In vivo pharmacokinetic parameters of 5-hydroxylansoprazole in rats (–x ± S.D.,  n = 6)
Parameters Control group Caffeine Tea polyphenol Daidzein
AUC (μg/L.h) 140.76 ± 62.62 108.23 ± 31.76 109.12 ± 68.98 116.73 ± 31.64
MRT (h) 1.52 ± 0.38 1.30 ± 0.46 1.11 ± 0.73 1.02 ± 0.18
T1/2 (h) 2.10 ± 1.36 2.24 ± 1.22 1.37 ± 1.51 1.42 ± 0.59
Tmax (h) 0.22 ± 0.04 0.22 ± 0.07 0.22 ± 0.15 0.22 ± 0.09
CL (L/h/kg) 60.33 ± 31.89 70.87 ± 21.69 91.63 ± 70.41 66.95 ± 18.85
Cmax (μg/L) 106.83 ± 28.53 136.43 ± 53.91 132.50 ± 36.47 127.83 ± 37.14
TABLE III - In vivo pharmacokinetic parameters of lansoprazole sulfone in rats (–x ± S.D.,  n = 6)
Parameters Control group Caffeine Tea polyphenol Daidzein
AUC (μg/L.h) 268.82 ± 82.37 240.16 ± 124.42 177.72 ± 29.73* 116.23 ± 40.14*
MRT (h) 1.42 ± 0.29 1.35 ± 0.66 1.43 ± 0.18 1.05 ± 0.22
T1/2 (h) 1.47 ± 0.57 12.46 ± 18.42 1.18 ± 0.13 1.50 ± 1.26
Tmax (h) 0.40 ± 0.20 0.23 ± 0.06 0.29 ± 0.11 0.40 ± 0.11
CL (L/h/kg) 31.24 ± 12.07 28.68 ± 21.44 44.76 ± 6.76* 69.04 ± 20.96*
Cmax (μg/L) 170.08 ± 31.51 166.23 ± 79.28 128.68 ± 28.98* 103.85 ± 39.20*
*p < 0.05 compared with the control group.
FIGURE 3 - Plasma concentration-time profiles of lansoprazole sulfone in rats after a single 8 mg·kg-1 oral dose of lansoprazole in 
groups with different pretreatments for two weeks. The values shown are the mean ± S.D. of six rats.
(Rodrigues et al., 2014; Boddu et al., 2009). Cytochrome 
P450 enzymes are most closely associated with drug 
metabolism, including CYP3A as the most critical 
ingredient and CYP2C as a huge subfamily. Lansoprazole 
is primarily metabolized by CYP3A and CYP2C19, 
alterations of which may influence the effects of proton 
pump inhibitors. In this study, we attempted to explore 
the effects of the common dietary factors caffeine, tea 
polyphenol and daidzein on the in vivo pharmacokinetics 
of lansoprazole and its metabolites in rats.
Caffeine, which is widely distributed in food and 
beverages, is metabolized almost completely by the liver. 
The metabolism of caffeine that involves the competition 
between many enzymes enables it to determine CYP1A2 
effectively as a probe drug (Hakooz, 2009). Regardless, 
the impact of caffeine on proton pump inhibitors or 
CYP2C19 and CYP3A has not been reported previously. 
The results herein suggested that caffeine had no effect on 
lansoprazole and its two main metabolites.
Tea is habitually drunk in Asia and the UK. Tea 
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polyphenol, as the main biologically active ingredient in 
tea, accounts for 20-30% of the dry weight. Moreover, 
tea polyphenol has extensively been used in food 
manufacturing as an additive because it is a potent 
antioxidant. In recent years, the influence of tea polyphenol 
on enzyme metabolism has been studied. Engdal and 
Nilsen found that green tea inhibited (IC50: 73 μg/mL) 
the in vitro metabolism of CYP3A4 that was expressed 
from c-DNA baculovirus utilizing testosterone as the 
substrate (Engdal, Nilsen, 2009). This study found 
that tea polyphenol significantly increased the AUC of 
lansoprazole, indicating that tea polyphenol suppressed 
the in vivo metabolism of lansoprazole. Meanwhile, the 
detection of metabolites revealed that tea polyphenol did 
not affect the metabolic product 5-hydroxylansoprazole 
mediated by CYP2C19, whereas it remarkably reduced 
the AUC and Cmax of lansoprazole sulfone metabolized 
by CYP3A. These results suggest that tea polyphenol may 
inhibit the CYP3A activity in vivo, thereby elevating the 
plasma concentration of lansoprazole.
Soy products, such as soy milk, tofu and soy sauce, 
are widely available in daily life. The consumption of 
fermented soybean products is gradually increasing 
around the world, due to their various health benefits 
(Kim et al., 2010). Genistein, flavones and isoflavones 
in soy can inhibit the activity of CYP3A4 (Scott et al., 
2008). High-content daidzein, which is a soy isoflavone, 
has been detected in celery and arrowroot. In addition, 
daidzein is pharmacologically capable of treating coronary 
heart disease, hypertension and hyperlipidemia, resisting 
tumors and preventing osteoporosis. Thus, daidzein has 
been clinically applied. Foster et al. reported that daidzein 
inhibited the in vitro activity of human liver microsomal 
enzyme CYP3A4 (Foster et al., 2003). In this study, 
daidzein increased the AUC of lansoprazole and reduced 
the AUC of lansoprazole sulfone but maintained the 
pharmacokinetics of 5-hydroxylansoprazole. The results 
reveal that daidzein may inhibit the in vivo metabolism of 
lansoprazole by suppressing the activity of CYP3A.
Detecting the plasma concentrations of lansoprazole 
and its two main metabolites in rats by mass spectrometry 
demonstrated that tea polyphenol and daidzein probably 
suppressed the metabolism of lansoprazole by inhibiting 
CYP3A activity, while caffeine barely influenced the 
pharmacokinetic parameters of lansoprazole. This study 
provides a reference for future dietary recommendations 
in the case of clinically used proton pump inhibitors. This 
report is on the rat CYP-related interaction; a human CYP 
transgenic animal study is ongoing. 
CONCLUSIONS
Tea polyphenol and daidzein may inhibit the in vivo 
metabolism of lansoprazole by suppressing the activity 
of CYP3A, thereby raising the plasma concentration of 
lansoprazole.
REFERENCES
BODDU, S.P.;  YAMSANI, M.R.;  POTHARAJU, S.; 
VEERARAGHAVAN, S.; RAJAK, S.; KUMA, S.V.; 
AVERY, B.A.; REPKA, M.A.; VARANASI, V.S. Influence 
of grapefruit juice on the pharmacokinetics of diltiazem 
in Wistar rats upon single and multiple dosage regimens. 
Pharmazie, v.64, p.525-531, 2009.
BRITTO, M.R.; MCKEAN, H.E.; BRUCKNER, G.G.; 
WEDLUND, P.J. Polymorphisms in oxidative drug 
metabolism: relationship to food preference. Br. J. Clin. 
Pharmac., v.32, p.235-237, 1991.
ENGDAL, S.; NILSEN, O.G. In vitro inhibition of CYP3A4 
by herbal remedies frequently used by cancer patients. 
Phytother. Res., v.23, p.906-912, 2009.
FOSTER, B.C.; VANDENHOEK, S.; HANA, J.; KRANTIS, 
A.; AKHTAR, M.H.; BRYAN, M.; BUDZINSKI, J.W.; 
RAMPUTH, A.; ARNASON, J.T. In vitro inhibition of 
human cytochrome P450-mediated metabolism of marker 
substrates by natural products. Phytomedicine, v.10, p.334-
342, 2003.
HAKOOZ, N.M. Caffeine metabolic ratios for the in vivo 
evaluation of CYP1A2, N-acetyltransferase 2, xanthine 
oxidase and CYP2A6 enzymatic activities. Curr. Drug 
Metab., v.10, p.329-338, 2009.
INOUE, M.; OKADA, H.; HORI, S.; KAWAHARA, Y.; 
KAWANO, S.; TAKENAKA, R.; TOYOKAWA, T.; 
ONISHI, Y.; SHIRATORI, Y.; YAMAMOTO, K. Does 
pretreatment with lansoprazole influence Helicobacter 
pylori eradication rate and quality of life? Digestion, v.81, 
p.218-222, 2010.
KIM, H.G.; HONG, J.H.; SONG, C.K.; SHIN, H.W.; KIM, 
K.O. Sensory characteristics and consumer acceptability 
of fermented soybean paste (Doenjang). J. Food Sci., v.75, 
p.S375-S383, 2010.
Effects of caffeine, tea polyphenol and daidzein on the pharmacokinetics of lansoprazole and its metabolites in rats 899
LIU, D.; XIANG, D.; REN, X. Determination of Lansoprazole 
and its metabolites in rat plasma by HPLC-MS/MS. China 
Pharmacist, v.14, p.176-179, 2011.
NOWACK, R. Review article: cytochrome P450 enzyme, and 
transport protein mediated herb-drug interactions in renal 
transplant patients: grapefruit juice, St John’s Wort - and 
beyond! Nephrology, v.13, p.337-347, 2008.
RODRIGUES, M.; ALVES, G.; FRANCISCO, J.; FORTUNA, 
A.; FALCÃO, A. Herb-drug Pharmacokinetic Interaction 
between Carica Papaya Extract and Amiodarone in Rats. 
J. Pharm. Pharm. Sci., v.17, p.302-315, 2014.
SAITO, M.; YASUI-FURUKORI, N.; UNO, T.; TAKAHATA, 
T.; SUGAWARA, K.; MUNAKATA, A.; TATEISHI, T. 
Effects of clarithromycin on lansoprazole pharmacokinetics 
between CYP2C19 genotypes. Br. J. Clin. Pharmacol., v.59, 
p.302-309, 2005.
SCOTT, L.M.; DURANT, P.; LEONE-KABLER, S.; WOOD, 
C.E.; REGISTER, T.C.; TOWNSEND, A.; CLINE, J.M. 
Effects of prior oral contraceptive use and soy isoflavonoids 
on estrogen-metabolizing cytochrome P450 enzymes. J. 
Steroid Biochem. Mol. Biol., v.112, p.179-185, 2008.
SPENCER, C.M.; FAULDS, D. Lansoprazole: a reappraisal of 
its pharmacodynamic and pharmacokinetic properties, and 
its therapeutic efficacy in acid-related disorders. Drugs, 
v.48, p.404-430, 1994.
XIANG, D.; XU, Y.; REN, X.; LIU, D. Effect of furazolidone on 
the pharmacokinetics of lansoprazole and its metabolites in 
rats. Chinese Pharm. J., v.47, p.458-461, 2012.
ZHANG, D.; YANG, M.; LIU, M.; ZHANG, Y.; WANG, X.; 
XIAO, X.; LIU, H. Pharmacokinetics of lansoprazole and its 
main metabolites after single intravenous doses in healthy 
Chinese subjects. Xenobiotica, v.11, p.1156-1162, 2012.
Received for publication on 05th November 2014
Accepted for publication on 28th July 2015

